

Please replace the paragraph beginning on page 15, line 1, with the following rewritten paragraph:

A¹ -- FIG. 1 is a graph of testosterone concentrations (\square), DHT concentrations (\bullet), and the DHT/T ratio for patients receiving a subdermal testosterone pellet implant over a period of 300 days after implantation. --

Please replace the paragraph beginning on page 15, line 7, with the following rewritten paragraph:

A² -- FIG. 3 is a 24-hour testosterone pharmacokinetic profile for patients receiving the TESTODERM[®] TTS patch (\blacksquare), as compared to baseline testosterone serum concentration levels (\bullet). --

Please replace the paragraph beginning on page 15, line 11, with the following rewritten paragraph:

A³ -- FIG. 5(a) is a graph showing the 24-hour testosterone pharmacokinetic profile for hypogonadal men prior to receiving 5.0 g/day of AndroGel[®] (- - -), 10.0 g/day of AndroGel[®] (— —), or the testosterone patch (——) (by initial treatment group). Normal high and low testosterone levels (ng/dl) are represented by the (— - - —) line. --

Please replace the paragraph beginning on page 15, line 14, with the following rewritten paragraph:

A⁴ -- FIG. 5(b) is a graph showing the 24-hour testosterone pharmacokinetic profile for hypogonadal men on the first day of treatment with either 5.0 g/day of AndroGel[®] (- - -), 10.0

A4 cont.

g/day of AndroGel® (— —), or the testosterone patch (——) (by initial treatment group).

Normal high and low testosterone levels (ng/dl) are represented by the (— - - — -) line. --

Please replace the paragraph beginning on page 15, line 17, with the following rewritten paragraph:

A5 cont.

-- FIG. 5(c) is a graph showing the 24-hour testosterone pharmacokinetic profile for hypogonadal men on day 30 of treatment with either 5.0 g/day of AndroGel® (- - - -), 10.0 g/day of AndroGel® (— —), or the testosterone patch (——) (by initial treatment group). Normal high and low testosterone levels (ng/dl) are represented by the (— - - — -) line. --

Please replace the paragraph beginning on page 15, line 20, with the following rewritten paragraph:

A6

-- FIG. 5(d) is a graph showing the 24-hour testosterone pharmacokinetic profile for hypogonadal men on day 90 of treatment with either 5.0 g/day of AndroGel® (- - - -), 10.0 g/day of AndroGel® (— —), or the testosterone patch (——) (by initial treatment group). Normal high and low testosterone levels (ng/dl) are represented by the (— - - — -) line. --

Please replace the paragraph beginning on page 16, line 1, with the following rewritten paragraph:

A7

-- FIG. 5(e) is a graph showing the 24-hour testosterone pharmacokinetic profile for hypogonadal men on day 180 of treatment with either 5.0 g/day of AndroGel® (- - - -), 7.5 g/day of AndroGel® (— - -), 10.0 g/day of AndroGel® (— —), or the testosterone patch (——) (by

A7 cont.

final treatment group). Normal high and low testosterone levels (ng/dl) are represented by the (— — — —) line. --

Please replace the paragraph beginning on page 16, line 4, with the following rewritten paragraph:

A8 -- FIG. 5(f) is a graph showing the 24-hour testosterone pharmacokinetic profile for hypogonadal men on day 0 (- - - -), 1 (— —), 30 (—), 90 (— - -), and 180 (—) of treatment with 5.0 g/day of AndroGel®. Normal high and low testosterone levels (ng/dl) are represented by the (— — — —) line. --

Please replace the paragraph beginning on page 16, line 6, with the following rewritten paragraph:

A9 -- FIG. 5(g) is a graph showing the 24-hour testosterone pharmacokinetic profile for hypogonadal men on day 0 (- - - -), 1 (— —), 30 (—), 90 (— - -), and 180 (—) of treatment with 10.0 g/day of AndroGel®. Normal high and low testosterone levels (ng/dl) are represented by the (— — — —) line. --

Please replace the paragraph beginning on page 16, line 8, with the following rewritten paragraph:

A10 -- FIG. 5(h) is a graph showing the 24-hour testosterone pharmacokinetic profile for hypogonadal men on day 0 (- - - -), 1 (— —), 30 (—), 90 (— - -), and 180 (—) of treatment with the testosterone patch. Normal high and low testosterone levels (ng/dl) are represented by the (— — — —) line. --

Please replace the paragraph beginning on page 16, line 10, with the following rewritten paragraph:

A¹¹ -- FIG. 6(a) is a graph showing the 24-hour free testosterone pharmacokinetic profile for hypogonadal men on day 1 of treatment with either 5.0 g/day of AndroGel[®] (- - - -), 10.0 g/day of AndroGel[®] (— —), or the testosterone patch (——) (by initial treatment group). Normal high and low testosterone levels (ng/dl) are represented by the (— - - — -) line. --

Please replace the paragraph beginning on page 16, line 13, with the following rewritten paragraph:

A¹² -- FIG. 6(b) is a graph showing the 24-hour free testosterone pharmacokinetic profile for hypogonadal men on day 30 of treatment with either 5.0 g/day of AndroGel[®] (- - - -), 10.0 g/day of AndroGel[®] (— —), or the testosterone patch (——) (by initial treatment group). Normal high and low testosterone levels (ng/dl) are represented by the (— - - — -) line. --

Please replace the paragraph beginning on page 16, line 16, with the following rewritten paragraph:

A¹³ -- FIG. 6(c) is a graph showing the 24-hour free testosterone pharmacokinetic profile for hypogonadal men on day 90 of treatment with either 5.0 g/day of AndroGel[®] (- - - -), 10.0 g/day of AndroGel[®] (— —), or the testosterone patch (——) (by initial treatment group). Normal high and low testosterone levels (ng/dl) are represented by the (— - - — -) line. --

Please replace the paragraph beginning on page 16, line 19, with the following rewritten paragraph:

A14

-- FIG. 6(d) is a graph showing the 24-hour free testosterone pharmacokinetic profile for hypogonadal men on day 180 of treatment with either 5.0 g/day of AndroGel® (- - - -), 10.0 g/day of AndroGel® (— —), or the testosterone patch (——) (by initial treatment group). Normal high and low testosterone levels (ng/dl) are represented by the (— - - — -) line. --

Please replace the paragraph beginning on page 16, line 22, with the following rewritten paragraph:

A15

-- FIG. 6(e) is a graph showing the 24-hour free testosterone pharmacokinetic profile for hypogonadal men on day 0 (- - - -), 1 (— —), 30 (——), 90 (— - -), and 180 (——) of treatment with 5.0 g/day of AndroGel®. Normal high and low testosterone levels (ng/dl) are represented by the (— - - — -) line. --

Please replace the paragraph beginning on page 17, line 1, with the following rewritten paragraph:

A16

-- FIG. 6(f) is a graph showing the 24-hour free testosterone pharmacokinetic profile for hypogonadal men on day 0 (- - - -), 1 (— —), 30 (——), 90 (— - -), and 180 (——) of treatment with 10.0 g/day of AndroGel®. Normal high and low testosterone levels (ng/dl) are represented by the (— - - — -) line. --

Please replace the paragraph beginning on page 17, line 3, with the following rewritten paragraph:

A¹⁷ -- FIG. 6(g) is a graph showing the 24-hour free testosterone pharmacokinetic profile for hypogonadal men on day 0 (- - - -), 1 (— —), 30 (—), 90 (— - -), and 180 (—) of treatment with the testosterone patch. Normal high and low testosterone levels (ng/dl) are represented by the (— - - -) line. --

Please replace the paragraph beginning on page 17, line 5, with the following rewritten paragraph:

A¹⁸ -- FIG. 7 is a graph showing the DHT concentrations on days 0 through 180 for hypogonadal men receiving either 5.0 g/day of AndroGel[®] (- - - -), 10.0 g/day of AndroGel[®] (— —), or the testosterone patch (—) (by initial treatment group). Normal high and low testosterone levels (ng/dl) are represented by the (— - - -) line. --

Please replace the paragraph beginning on page 17, line 8, with the following rewritten paragraph:

A¹⁹ -- FIG. 8 is a graph showing the DHT/T ratio on days 0 through 180 for hypogonadal men receiving either 5.0 g/day of AndroGel[®] (- - - -), 10.0 g/day of AndroGel[®] (— —), or the testosterone patch (—) (by initial treatment group). Normal high and low testosterone levels (ng/dl) are represented by the (— - - -) line. --

Please replace the paragraph beginning on page 17, line 11, with the following rewritten paragraph:

A²⁰ -- FIG. 9 is a graph showing the total androgen concentrations (DHT +T) on days 0 through 180 for hypogonadal men receiving either 5.0 g/day of AndroGel[®] (- - - -), 10.0 g/day of

A20 cont.
AndroGel® (— —), or the testosterone patch (——) (by initial treatment group). Normal high and low testosterone levels (ng/dl) are represented by the (— - - — -) line. --

Please replace the paragraph beginning on page 17, line 14, with the following rewritten paragraph:

A21
-- FIG. 10 is a graph showing the E₂ concentrations on days 0 through 180 for hypogonadal men receiving either 5.0 g/day of AndroGel® (- - - -), 10.0 g/day of AndroGel® (— —), or the testosterone patch (——) (by initial treatment group). Normal high and low testosterone levels (ng/dl) are represented by the (— - - — -) line. --

Please replace the paragraph beginning on page 17, line 17, with the following rewritten paragraph:

A22
-- FIG. 11 is a graph showing the SHBG concentrations on days 0 through 180 for hypogonadal men receiving either 5.0 g/day of AndroGel® (- - - -), 10.0 g/day of AndroGel® (— —), or the testosterone patch (——) (by initial treatment group). Normal high and low testosterone levels (ng/dl) are represented by the (— - - — -) line. --

Please replace the paragraph beginning on page 17, line 20, with the following rewritten paragraph:

A23
-- FIG. 12(a) is a graph showing the FSH concentrations on days 0 through 180 for men having primary hypogonadism and receiving either 5.0 g/day of AndroGel® (- - - -), 10.0 g/day of AndroGel® (— —), or the testosterone patch (——) (by initial treatment group). Normal high and low testosterone levels (ng/dl) are represented by the (— - - — -) line. --

Please replace the paragraph beginning on page 18, line 1, with the following rewritten paragraph:

A24 -- FIG. 12(b) is a graph showing the FSH concentrations on days 0 through 180 for men having secondary hypogonadism and receiving either 5.0 g/day of AndroGel® (- - - -), 10.0 g/day of AndroGel® (— —), or the testosterone patch (——) (by initial treatment group). Normal high and low testosterone levels (ng/dl) are represented by the (— - - — -) line. Normal high and low testosterone levels (ng/dl) are represented by the (— - - — -) line. --

Please replace the paragraph beginning on page 18, line 4, with the following rewritten paragraph:

A25 -- FIG. 12(c) is a graph showing the FSH concentrations on days 0 through 180 for men having age-associated hypogonadism and receiving either 5.0 g/day of AndroGel® (- - - -), 10.0 g/day of AndroGel® (— —), or the testosterone patch (——) (by initial treatment group). Normal high and low testosterone levels (ng/dl) are represented by the (— - - — -) line. --

Please replace the paragraph beginning on page 18, line 7, with the following rewritten paragraph:

A26 -- FIG. 12(d) is a graph showing the FSH concentrations on days 0 through 180 for men having hypogonadism of an unknown origin and receiving either 5.0 g/day of AndroGel® (- - - -), 10.0 g/day of AndroGel® (— —), or the testosterone patch (——) (by initial treatment group). Normal high and low testosterone levels (ng/dl) are represented by the (— - - — -) line. --

Please replace the paragraph beginning on page 18, line 10, with the following rewritten paragraph:

-- FIG. 13(a) is a graph showing the LH concentrations on days 0 through 180 for men having primary hypogonadism and receiving either 5.0 g/day of AndroGel® (- - -), 10.0 g/day of AndroGel® (— —), or the testosterone patch (——) (by initial treatment group). Normal high and low testosterone levels (ng/dl) are represented by the (— - - — -) line. --

A27
[Please replace the paragraph beginning on page 18, line 13, with the following rewritten paragraph:]

-- FIG. 13(b) is a graph showing the LH concentrations on days 0 through 180 for men having secondary hypogonadism and receiving either 5.0 g/day of AndroGel® (- - -), 10.0 g/day of AndroGel® (— —), or the testosterone patch (——) (by initial treatment group). Normal high and low testosterone levels (ng/dl) are represented by the (— - - — -) line. --

[Please replace the paragraph beginning on page 18, line 16, with the following rewritten paragraph:]

-- FIG. 13(c) is a graph showing the LH concentrations on days 0 through 180 for men having age-associated hypogonadism and receiving either 5.0 g/day of AndroGel® (- - -), 10.0 g/day of AndroGel® (— —), or the testosterone patch (——) (by initial treatment group). Normal high and low testosterone levels (ng/dl) are represented by the (— - - — -) line. --

Please replace the paragraph beginning on page 18, line 19, with the following rewritten paragraph:

A28
-- FIG. 13(d) is a graph showing the LH concentrations on days 0 through 180 for men having hypogonadism of an unknown origin and receiving either 5.0 g/day of AndroGel® (- - -), 10.0 g/day of AndroGel® (— —), or the testosterone patch (——) (by initial treatment group). Normal high and low testosterone levels (ng/dl) are represented by the (— - - —) line. --

Please replace the paragraph beginning on page 19, line 1, with the following rewritten paragraph:

A29
-- FIG. 14(a) is a bar graph showing the change in hip BMD for hypogonadal men after 180 days of treatment with 5.0 g/day of AndroGel® (☒), 5.0 g/day of AndroGel® switched to 7.5 g/day of AndroGel® (wide hatch mark), 10.0 g/day of AndroGel® switched to 7.5 g/day of AndroGel® (narrow hatch marks), 10.0 g/day of AndroGel® (■), or the testosterone patch (□). --

[Please replace the paragraph beginning on page 19, line 4, with the following rewritten paragraph:]

-- FIG. 14(b) is a bar graph showing the change in spine BMD for hypogonadal men after 180 days of treatment with 5.0 g/day of AndroGel® (☒), 5.0 g/day of AndroGel® switched to 7.5 g/day of AndroGel® (wide hatch mark), 10.0 g/day of AndroGel® switched to 7.5 g/day of AndroGel® (narrow hatch marks), 10.0 g/day of AndroGel® (■), or the testosterone patch (□). --

Please replace the paragraph beginning on page 19, line 7, with the following rewritten paragraph:

A30
-- FIG. 15 is a graph showing PTH concentrations on days 0 through 180 for hypogonadal men receiving either 5.0 g/day of AndroGel® (- - -), 10.0 g/day of AndroGel® (—

—), or the testosterone patch (—) (by initial treatment group). Normal high and low testosterone levels (ng/dl) are represented by the (— - - —) line. --

[Please replace the paragraph beginning on page 19, line 10, with the following rewritten paragraph:]

-- FIG. 16 is a graph showing SALP concentrations on days 0 through 180 for hypogonadal men receiving either 5.0 g/day of AndroGel® (- - - -), 10.0 g/day of AndroGel® (— — — —), or the testosterone patch (—) (by initial treatment group). Normal high and low testosterone levels (ng/dl) are represented by the (— - - —) line. --

A30-1
A Cont. [Please replace the paragraph beginning on page 19, line 13, with the following rewritten paragraph:]

-- FIG. 17 is a graph showing the osteocalcin concentrations on days 0 through 180 for hypogonadal men receiving either 5.0 g/day of AndroGel® (- - - -), 10.0 g/day of AndroGel® (— — — —), or the testosterone patch (—) (by initial treatment group). Normal high and low testosterone levels (ng/dl) are represented by the (— - - —) line. --

[Please replace the paragraph beginning on page 19, line 16, with the following rewritten paragraph:]

-- FIG. 18 is a graph showing the type I procollagen concentrations on days 0 through 180 for hypogonadal men receiving either 5.0 g/day of AndroGel® (- - - -), 10.0 g/day of AndroGel® (— — — —), or the testosterone patch (—) (by initial treatment group). Normal high and low testosterone levels (ng/dl) are represented by the (— - - —) line. --

Please replace the paragraph beginning on page 19, line 19, with the following rewritten paragraph:

A31 -- FIG. 19 is a graph showing the N-telopeptide/Cr ratio on days 0 through 180 for hypogonadal men receiving either 5.0 g/day of AndroGel® (- - -), 10.0 g/day of AndroGel® (— —), or the testosterone patch (——) (by initial treatment group). Normal high and low testosterone levels (ng/dl) are represented by the (— - - — -) line. --

Please replace the paragraph beginning on page 20, line 1, with the following rewritten paragraph:

A32 -- FIG. 20 is a graph showing the Ca/Cr ratio on days 0 through 180 for hypogonadal men receiving either 5.0 g/day of AndroGel® (- - -), 10.0 g/day of AndroGel® (— —), or the testosterone patch (——) (by initial treatment group). Normal high and low testosterone levels (ng/dl) are represented by the (— - - — -) line. --

Please replace the paragraph beginning on page 21, line 7, with the following rewritten paragraph:

A33 Sub 810 -- FIG. 24(a) is a bar graph showing the change in leg strength on days 90 and 180 for hypogonadal men receiving either 5.0 g/day of AndroGel® (diagonal hatch marks), 7.5 g/day of AndroGel® (horizontal hatch marks), 10.0 g/day of AndroGel® (⊠), or the testosterone patch (□). --

A33 cont.
[Please replace the paragraph beginning on page 21, line 10, with the following rewritten paragraph:]

Sub B cont.
-- FIG. 24(b) is a bar graph showing the change in arm strength on days 90 and 180 for hypogonadal men receiving either 5.0 g/day of AndroGel® (diagonal hatch marks), 7.5 g/day of AndroGel® (horizontal hatch marks), 10.0 g/day of AndroGel® (☒), or the testosterone patch (□). --

[Please replace the paragraph beginning on page 21, line 13, with the following rewritten paragraph:]

Sub B
-- FIG. 25(a) is a bar graph showing the change in total body mass on days 90 and 180 for hypogonadal men receiving either 5.0 g/day of AndroGel® (diagonal hatch marks), 7.5 g/day of AndroGel® (horizontal hatch marks), 10.0 g/day of AndroGel® (☒), or the testosterone patch (□). --

[Please replace the paragraph beginning on page 21, line 16, with the following rewritten paragraph:]

-- FIG. 25(b) is a bar graph showing the change in lean body mass on days 90 and 180 for hypogonadal men receiving either 5.0 g/day of AndroGel® (diagonal hatch marks), 7.5 g/day of AndroGel® (horizontal hatch marks), 10.0 g/day of AndroGel® (☒), or the testosterone patch (□). --

[Please replace the paragraph beginning on page 21, line 19, with the following rewritten paragraph:]

Sub 812
A33-1
Acmt.

-- FIG. 25(c) is a bar graph showing the change in fat mass on days 90 and 180 for hypogonadal men receiving either 5.0 g/day of AndroGel® (diagonal hatch marks), 7.5 g/day of AndroGel® (horizontal hatch marks), 10.0 g/day of AndroGel® (☒), or the testosterone patch (□). --

[Please replace the paragraph beginning on page 22, line 1, with the following rewritten paragraph:]

-- FIG. 25(d) is a bar graph showing the change in percent body fat on days 90 and 180 for hypogonadal men receiving either 5.0 g/day of AndroGel® (diagonal hatch marks), 7.5 g/day of AndroGel® (horizontal hatch marks), 10.0 g/day of AndroGel® (☒), or the testosterone patch (□). --